Quinton Oswald, CEO of Notal Vision, introduced the company’s ForeseeHome diagnostic tool for wet age-related macular degeneration (AMD). The company is looking to move diagnosis of the vision-deteriorating disease out of the physician’s office where identifying the disease might come too late to save and partially restore vision with anti-VEGF therapies. Oswald said 70% of patients no longer have functional vision at the time of diagnosis with optical coherence tomography (OCT), often suffering 18-line declines of vision. Patients using Foresee can track the progression of dry AMD to wet AMD sooner, he said. The company’s system is FDA approved and currently is being used by 3,000 patients who are able to test themselves four to five times per week. More than 2 million tests have been done, he said.
Mr. Oswald brings extensive ophthalmic development and commercialization experience to Notal Vision, previously holding CEO positions with Neurotech and SARcode Bioscience.